For complete list of publications:
Google Scholar
ORCID
Publons
http://www.ncbi.nlm.nih.gov/sites/myncbi/1fmKRSBQZ7m5C/bibliography/41539585/public/?sort=date&direction=descending
Publications (# equal contribution * Corresponding author, undergraduate co-authors)
At the University of Arizona
94. Ma C,# Xia Z,# Sacco MD, Hu Y, Townsend JA, Meng X, Choza J, Tan H, Jang J, Gongora MV, Zhang X, Zhang F, Xiang Y, Marty MT, Chen Y,* Wang J.* Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. J. Am. Chem. Soc. 2021 Dec 3. doi: 10.1021/jacs.1c08060. Link
93. Townsend JA, Sanders HM, Rolland AD, Park CK, Horton NC, Prell JS, Wang J, Marty MT.* Influenza AM2 Channel Oligomerization Is Sensitive to Its Chemical Environment. Anal. Chem. 2021 Nov 23. doi: 10.1021/acs.analchem.1c04660. Epub ahead of print. Link
92. Ma C, Tan H, Choza J, Wang Y, Wang J.* Validation and invalidation of SARS-CoV-2 main protease inhibitors using the FlipGFP and Protease-Glo luciferase assays. Acta Pharm. Sin. B 2021 ASAP
91. Boras B, Jones RM,* Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O' Brien MN, O'Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rosales R, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, White KM, García-Sastre A, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun. 2021 Oct 18;12(1):6055. doi: 10.1038/s41467-021-26239-2. PMID: 34663813.
90. Cáceres, C. J.; Hu, Y.; Cárdenas-García, S.; Tan, H.; Wu, X.; Carnaccini, S.; Gay, L. C.; Geiger, G.; Ma, C.; Zhang, Q.-Y.; Rajao, D.; Perez, D. R.;* Wang, J.,* Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses. Emerging Microbes & Infections 2021, 1-38. PubMed.
89. Wang J,* Hu Y, Zheng, M. Enterovirus 71 antivirals: past, present, and future.
Acta Pharm. Sin. B. 2021. doi.org/10.1016/j.apsb.2021.08.017 PubMed.
88. Thomaston JL, Samways ML, Konstantinidi A, Ma C, Hu Y, Bruce Macdonald HE, Wang J, Essex JW, DeGrado WF,* Kolocouris A.* Rimantadine Binds to and Inhibits the Influenza A M2 Proton Channel without Enantiomeric Specificity. Biochemistry. 2021. Aug 3. doi: 10.1021/acs.biochem.1c00437. PubMed.
87. Xia Z,# Sacco M,# Hu Y, Ma C, Meng X, Zhang F, Szeto T, Xiang Y, Chen Y,* Wang J.* Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir. ACS Pharmacol. Transl. Sci. 2021. doi: 10.1021/acsptsci.1c00099. PubMed.
86. Ma C,# Sacco MD,# Xia Z,# Lambrinidis G, Townsend JA, Hu Y, Meng X, Szeto T, Ba M, Zhang X, Gongora M, Zhang F, Marty MT, Xiang Y, Kolocouris A, Chen Y,* Wang J.* Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay.
ACS Cent. Sci. 2021. doi: 10.1021/acscentsci.1c00519. PubMed.
85. Hu Y,# Kitamura N,# Musharrafieh R, Wang J.* Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein.
J. Med. Chem. 2021 Jun 4. doi: 10.1021/acs.jmedchem.1c00758. Epub ahead of print. PMID: 34085827. PubMed.
84. Zhao H, Jiang S, Ye Z, Zhu H, Hu B, Meng P, Hu Y, Zhang H, Wang K,* Wang J,* Tian Y.* Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase. Eur. J. Med. Chem. 2021 May 23;221:113567. doi: 10.1016/j.ejmech.2021.113567. Epub ahead of print. PMID: 34082224. PubMed.
83. Cáceres CJ, Cardenas-Garcia S, Carnaccini S, Seibert B, Rajao DS, Wang J,* Perez DR.* Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci. Rep. 2021 May 5;11(1):9609. doi: 10.1038/s41598-021-89013-w. PMID: 33953295; PMCID: PMC8100161. PubMed.
82. Kitamura N, Sacco MD, Ma C, Hu Y, Townsend JA, Meng X, Zhang F, Zhang X, Ba M, Szeto T, Kukuljac A, Marty MT, Schultz D, Cherry S, Xiang Y, Chen Y,* Wang J.* (2021) Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. J. Med. Chem. 2021 Apr 23. doi: 10.1021/acs.jmedchem.1c00509. Epub ahead of print. PMID: 33891389. PubMed.
81. Hu, Y., Ma, C., Szeto, T., Hurst, B., Tarbet, B., Wang, J.* (2021) Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronavirues. ACS Infect. Dis. 7, 586-597. PubMed.
80. Hu, Y., Meng, X., Zhang, F., Xiang, Y., Wang, J.* (2021) The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor.
Emerg. Microbes & Infect. 10, 317-330. PubMed.
79. Ma, C., Wang, J.* (2021) Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc. Natl. Acad. Sci. U.S.A. 118, e2024420118. (Letter to the editor)
78. Sacco, M., Ma, C., Lagarias, P., Gao, A., Townsend, J., Meng, X., Dube, P., Zhang, X., Hu, Y., Kitamura, N., Hurst, B., Tarbet, B., Marty, M., Kolocouris, A., Chen, Y.,* Wang, J.* (2020) Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L. Sci. Adv. 6, eabe0751. PubMed.
77. Ma, C., Hu, Y., Townsend, J., Lagarias, P., Marty, M., Kolocouris, A., Wang, J.* (2020) Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors.
ACS Pharmacol. Transl. Sci. 3, 1265-1277. PubMed.
76. Tzitzoglaki, C., McGuire, K., Lagarias, P., Konstantinidi, A., Hoffmann, A., Fokina, N., Ma, C., Papanastasiou, I., Schreiner, P., Vazques, S., Schmidtke, M., Wang, J., Busath, D., Kolocouris, A.* (2020) Chemical probes for blocking of the influenza A M2 WT and S31N channels. ACS Chem. Biol. 15, 2331-2337. PubMed.
75. Ma, C., Hu, Y., Zhang, J., Wang, J.* (2020) Pharmacological characterization of the mechanism of action of R523062, a promising antiviral for enterovirus D68. ACS Infect. Dis. 6, 2260-2270. PubMed.
74. Cai, S., Tuohy, P., Ma, C., Kitamura, N., Gomez, K., Zhou, Y., Ran, D., Bellampalli, S., Yu, J., Luo, S., Dorame, A., Ngan, P., Nancy, Y., Molnar, G., Streicher, J., Patek, M., Perez-Miller, S., Moutal, A., Wang, J.,* Khanna, R.* (2020) A modulator of low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies. Pain 161, 2551-2570. PubMed.
73. Musharrafieh, R., Kitamura, N., Hu, Y., Wang, J.* (2020) Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. Bioorg. Chem. 101, 103981. PubMed.
72. Ma, C., Sacco, M., Hurst, B., Townsend, J., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M., Chen, Y.,* Wang, J.* (2020) Boceprevir, GC-376, and calpain inhibitors II and XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30, 678-692. PubMed.
71. Hu, Y., Musharrafieh R., Zheng, M., Wang, J.* (2020) Enterovirus D68 antivirals: past, present, and future.
ACS Infect. Dis. 6, 1572-1586. PubMed.
70. Musharrafieh R, Lagarias P, Ma CL, Hau, R, Romano A, Lambrinidis G, Kolocouris A,* Wang J.* (2020) Investigation of the drug resistance mechanism of M2-S31N channel blockers through biomolecular simulations and viral passage experiments. ACS Pharmacol. Trans. Sci. 3, 666-675. PubMed.
69. Jalily PH, Duncan MC, Fedida D, Wang J, Tietjen I.* (2020) Put a cork in it: plugging the M2 viral ion channel to sink influenza. Antiviral Res. 178, 104780. Pubmed.
68. Thomaston JL, Konstantinidi A, Liu L, Lambrinidis G, Tan J, Caffrey M, Wang J, Degrado WF,* Kolocouris A.* (2020) X-ray crystal structures of the influenza M2 proton channel drug-resistant V27A mutant bound to a spiro-adamantyl amine inhibitor reveal the mechanism of amantadine resistance. Biochemistry. 59, 627-634. Pubmed.
67. Zhang, J., Hu, Y., Wu, N., Wang, J.* (2020) Discovery of influenza polymerase PA-PB1 interaction inhibitors using an in vitro split-luciferase complementation-based assay. ACS Chem. Biol. 15, 74-82. PubMed.
66. Musharrafieh, R., Ma, C., Wang, J.* (2019) Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses. E. J. Pharm. Sci. 141, 105124. PubMed.
65. Ma, C., Zhang, J., Hu, Y., Musharrafieh, R., Wang, J.* (2019) A novel capsid binding inhibitor displays potent antiviral activity against enterovirus D68. ACS Infect. Dis. 5, 1952-1962.
64. Thomaston, J., Wu, Y., Polizzi, N., Liu, L., Wang, J., DeGrado, W.F.* (2019) X-ray crystal structure of the influenza A M2 proton channel S31N mutant in two conformational states: an open and shut case. J. Am. Chem. Soc. 141, 11481-11488. PubMed.
63. Musharrafieh, R., Lagarias, P., Ma, C., Tan, G., Kolocouris, A.,* Wang, J.* (2019) The L46P mutant confers a novel allosteric mechanism of resistance towards the influenza A virus M2 S31N proton channel blockers.
Mol. Pharmacol. 96, 148-157. PubMed.
62. Zhang, J., Hu, Y., Hau, R., Musharrafieh, R., Ma, C., Zhou, X., Chen, Y., Wang, J.* (2019) Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses.
Eur. J. Pharm. Sci. 133, 86-94. PubMed.
61. Musharrafieh, R., Zhang, J., Tuohy P., Kitamura N., Bellampalli S.S., Hu, Y., Khanna, R., Wang, J.* (2019) Discovery of quinoline analogous as potent antivirals against enterovirus D68 (EV-D68). J. Med. Chem. 62, 4074-4090. PubMed.
60. Musharrafieh, R., Ma, C., Zhang, J., Hu, Y., Diesing, J.M., Marty, M.T., Wang, J.* (2019)
Validating enterovirus D68 2Apro as an antiviral drug target and the discovery of telaprevir as a
potent EV-D68-2Apro inhibitor. J. Virol. 93, e02221-18. (Spotlight feature article). PubMed.
59. Hu, Y., Hau, R., Wang, Y., Tuohy, P., Zhang, Y., Xu, S., Ma, C., Wang, J.* (2018) Structure-property relationship studies of influenza A virus AM2-S31N proton channel blockers. ACS. Med. Chem. Lett. 9, 1111-1116. (highlighted by ScienceDaily, ACS PressPac, and EurekAlert). PubMed.
58. Thomaston JL, Polizzi NF, Konstantinidi A, Wang J, Kolocouris A,* DeGrado WF.* (2018) Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters. J. Am. Chem. Soc. 140, 15219-15226. PubMed.
57. Zhang, J., Hu, Y.M., Musharrafieh, R., Yin, H., Wang, J.* (2019) Focusing on the influenza polymerase complex: recent progress in drug discovery and assay development. Curr. Med. Chem. 26, 2243-2263. PubMed.
56. Zhao X, Li R, Zhou Y, Xiao M, Ma C, Yang Z, Zeng S, Du Q, Yang C, Jiang H, Hu Y, Wang K, Mok CKP, Sun P, Dong J, Cui W, Wang J, Tu Y, Yang Z, Hu W.* (2018) Discovery of highly potent pinanamine-based inhibitors against amantadine- and oseltamivir-resistant influenza A viruses. J. Med. Chem. 2018, 61, 5187-5198. PubMed.
55. Mandour YM, Breitinger U, Ma C, Wang J, Boeckler FM, Breitinger HG, Zlotos DP. (2018) Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.
Drug Des. Devel. Ther. 12, 1019-1031. PubMed.
54. Zhang, J., Hu, Y.M., Foley, C., Wang, Y.X., Musharrafieh, R., Xu, S.T., Zhang, Y.T., Ma, C.L., Hulme, C., Wang, J.* (2018) Exploring Ugi-azide four-component reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance. Sci. Rep. 8, 4653. PubMed.
53. Musharrafieh, R., Ma, C.L., Wang, J.* (2018) Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. Antiviral Res. 153, 10-22. PubMed.
52. Drakopoulos, A., Tzitzoglaki, C., McGuire, K., Hoffman, A., Konstantinidi, A., Kolokouris, D., Ma, C.L., Freudenberger, K., Hutterer, J., Gauglitz, G., Wang, J., Schmidtke, M., Busath, D., Kolocouris, A.* (2018) Unraveling the binding, proton blockage, and inhibition of influenza M2 WT and S31N by rimantadine variants.
ACS Med. Chem. Lett. 2018, 9, 198-203. PubMed.
51. Wang, Y. X., Hu, Y.M., Xu, S. T., Zhang, Y.T., Musharrafieh, R., Hau, R., Ma, C.L., Wang, J.* (2018) In vitro pharmacokinetic optimizations of AM2-S31N channel blockers led to the discovery of slow-binding inhibitors with potent antiviral activity against drug-resistant influenza A viruses. J. Med. Chem. 61, 1074-1085. PubMed
50. Ma, C.L., Wang, J.* (2018) Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses. Biochim. Biophys. Acta.-Biomembrane 1860, 272-280. PubMed
49. Williams, J.K., Shcherbakov, A.A., Wang, J., Hong, M.* (2017) Protonation equilibria and pore-opening structure of the dual-histidine influenza B virus M2 transmembrane proton channel from solid-state NMR.
J. Biol. Chem. 292, 17876-17884. PubMed
48. Hu, Y.M., Zhang, J.T., Musharrafieh, R., Hau, R., Ma, C.L., Wang, J.* (2017) Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral.
Int. J. Mol. Sci. 18, E1929. PubMed
47. Hu, Y.M., Zhang, J.T., Musharrafieh, R., Ma, C.L., Hau, R., Wang, J.* (2017) Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses. Antiviral Res. 145, 103-113. PubMed
46. Barniol-Xicota M, Gazzarrini S, Torres E, Hu Y, Wang J, Naesens L, Moroni A, Vazquez S.* (2017) Slow but steady wins the race: dissimilarities among new dual inhibitors of the wild-type and the V27A mutatn M2 channels of influenza A virus. J. Med. Chem. 60, 3727-3738. PubMed
45. Hu, Y.M., Wang, Y.X., Fang, L., Ma, C.L., Wang, J.* (2017) Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses. E. J. Med. Chem. 135, 70-76. PubMed
44. Hu, Y.M., Sneyd, H., Dekant, R., Wang, J.* (2017) Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target. Curr. Top. Med. Chem. 17, 2271-2285. PubMed
43. Li, F., Hu, Y.M., Wang, Y.X., Ma, C.L., Wang, J.* (2017) Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki–Miyaura Cross-Coupling Reaction J. Med. Chem. 60, 1580-1590. PubMed
42. Drakopoulos, A., Tzitzoglaki, C., Ma, C.L., Freudenberger, K. M., Hoffmann, A., Hu, Y.M., Gauglitz, G., Schmidtke, M., Wang, J.,* Kolocouris, A.,* (2017) Affinity of rimantadine enantiomers against Influenza A/M2 protein Revisited ACS Med. Chem. Lett. 8, 145-150. PubMed
41. Hu, Y.M., Musharrafieh, R., Ma, C.L., Zhang, J.T., Smee, D.F., DeGrado, W.F., Wang, J.* (2017) An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. Antiviral Res. 140, 45-54 PubMed
40. Li, F., Ma, C.L., Hu, Y.M., Wang, Y.X., Wang, J.* (2016) Discovery of potent antivirals against amantadine-resistant influenza A viruses by targeting the M2-S31N proton channel ACS Infect. Dis. 2, 726-133. PubMed
39. Ma, C.L., Li, F., Musharrafieh, R., Wang, J.* (2016) Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier to drug resistance. Antiviral Res. 133, 62-72. PubMed
38. Ma, C.L., Zhang, J.T., Wang, J.* (2016) Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic barrier of Drug Resistance of M2-S31N Channel Blockers. Mol. Pharmacol. mol.116.105346. PubMed
37. William, J.K., Tietze, D., Lee, M., Wang, J. Hong, M.* (2016) Solid-State NMR Investigation of the Conformation, Proton Conductance, and Hydration of the Influenza B Virus M2 Transmembrane Proton Channel.
J. Am. Chem. Soc. 138(26), 8143-8155. PubMed
36. Li, F., Ma, C.L., DeGrado, W.F., Wang, J.* (2016) Discovery of highly potent inhibitors targeting the predominant drug-resistant S31N mutant of the influenza A virus M2 proton channel. J. Med. Chem. 59(3), 1207-1216. PubMed
35. Wang, J.* (2016) M2 as a target to combat influenza drug resistance: what does the evidence say?
Future Virology (invited editorial) 11(1), 1-4.
34. Li, F., Ma, C.L., Wang, J.* (2015) Inhibitors Targeting the Influenza Virus Hemagglutinin. Curr. Med. Chem. 22, 1361-1382. PubMed
33. Wang, J.,* Li, F., and Ma, C.L. (2015) Recent Progress in Designing Inhibitors that Target the Drug-Resistant M2 Proton Channels from the Influenza A Viruses. Biopolymers: Peptide Science. 104, 291-309. PubMed
32. Wu, Y. B., Canturk, B., Jo, H., Ma, C. L., Gianti, E., Klein, M. L., Pinto, L. H., Lamb, R. A., Fiorin, G.,* Wang, J.,* and DeGrado, W. F.* (2014) Flipping in the pore: Discovery of Dual Inhibitors that Bind in Different Orientations to the Wild-Type versus the Amantadine-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.
J. Am. Chem. Soc. 136, 17987-13995. PubMed
At the University of California, San Francisco
31. Ghosh, A., Wang, J., Moroz, Y. S., Korendovych, I. V., Zanni, M. T., DeGrado, W. F., and Hochstrasser, R. M. (2014) 2D IR Spectroscopy Reveals the Role of Water in the Binding of Channel-Blocking Drugs to the Influenza M2 Channel. J Chem Phys 40, 235105.
30. Montalvo, G. L., Zhang, Y., Young, T. M., Costanzo, M. J., Freeman, K. B., Wang, J., Clements, D. J., Magavern, E., Kavash, R. W., Scott, R. W., Liu, D., and DeGrado, W. F. (2014) De Novo Design of Self-Assembling Foldamers That Inhibit Heparin-Protein Interactions. ACS Chem Biol 9, 967-975.
29. Rey-Carrizo, M., Torres, E., Ma, C., Barniol-Xicota, M., Wang, J., Wu, Y., Naesens, L., DeGrado, W. F., Lamb, R. A., Pinto, L. H., and Vazquez, S. (2013) M2 ion channel of influenza A virus: from wild-type inhibitors to compounds with potent activity against the V27A mutant. J Med Chem 56, 9265-9274.
28. Ma, C. L., Fiorin, G., Carnevale, V., Wang, J., Lamb, R. A., Klein, M. L., Wu, Y. B., Pinto, L. H., and DeGrado, W. F. (2013) Asp44 stabilizes the Trp41 gate of the M2 proton channel of influenza A virus. Structure 21, 2033-2041.
27. Wang, J., Wu, Y., Ma, C., Fiorin, G., Wang, J., Pinto, L. H., Lamb, R. A., Klein, M. L., and DeGrado, W. F. (2013 ) Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus.
Proc Natl Acad Sci U S A 110, 1315-1320. Highlighted by Science-Business eXchange (SciBX).
26. Williams, J. K., Tietze, D., Wang, J., Wu, Y., DeGrado, W. F., and Hong, M. (2013) Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR.
J Am Chem Soc 135, 9885-9897. Highlighted by JACS.
25. Wang, J., Ma, C., Wang, J., Jo, H., Canturk, B., Fiorin, G., Pinto, L. H., Lamb, R. A., Klein, M. L., and DeGrado, W. F. (2013) Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. J Med Chem 56, 2804-2812.
24. Thomaston, J. L., Nguyen, P. A., Brown, E. C., Upshur, M. A., Wang, J., DeGrado, W. F., and Howard, K. P. (2013) Detection of drug-induced conformational change of a transmembrane protein in lipid bilayers using site-directed spin labeling. Protein Sci 22, 65-73.
23. Schmidt, N. W., Mishra, A.,# Wang, J.,# DeGrado, W. F., and Wong, G. C. (2013) Influenza virus a m2 protein generates negative gaussian membrane curvature necessary for budding and scission. J Am Chem Soc 135, 13710-13719.
22. Mao, L., Wang, J., DeGrado, W. F., and Inouye, M. (2013) An assay suitable for high throughput screening of anti-influenza drugs. Plos One 8, e54070
21. Balgi, A. D.,# Wang, J.,# Cheng, D. Y., Ma, C., Pfeifer, T. A., Shimizu, Y., Anderson, H. J., Pinto, L. H., Lamb, R. A., DeGrado, W. F., and Roberge, M. (2013) Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay. Plos One 8, e55271.
At the University of Pennsylvania
20. Wang, J., Qiu, J. X., Soto, C., and DeGrado, W. F. (2011) Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr Opin Struct Biol 21, 68-80.
19. Wang, J., Ma, C., Wu, Y., Lamb, R. A., Pinto, L. H., and DeGrado, W. F. (2011) Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. J Am Chem Soc 133, 13844-13847. Highlighted by Faculty 1000.
18. Wang, J., Ma, C., Fiorin, G., Carnevale, V., Wang, T., Hu, F., Lamb, R. A., Pinto, L. H., Hong, M., Klein, M. L., and DeGrado, W. F. (2011) Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J Am Chem Soc 133, 12834-12841. Highligted by Faculty 1000.
17. Wang, J., Ma, C., Balannik, V., Pinto, L. H., Lamb, R. A., and DeGrado, W. F. (2011) Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. ACS Med Chem Lett 2, 307-312.
16. Rogers, J. M., Polishchuk, A. L., Guo, L., Wang, J., DeGrado, W. F., and Gai, F. (2011) Photoinduced electron transfer and fluorophore motion as a probe of the conformational dynamics of membrane proteins: application to the influenza a M2 proton channel. Langmuir 27, 3815-3821.
15. Duque, M. D., Ma, C., Torres, E., Wang, J., Naesens, L., Juarez-Jimenez, J., Camps, P., Luque, F. J., DeGrado, W. F., Lamb, R. A., Pinto, L. H., and Vazquez, S. (2011) Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. J Med Chem 54, 2646-2657.
14. Cady, S. D., Wang, J., Wu, Y., DeGrado, W. F., and Hong, M. (2011) Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. J Am Chem Soc 133, 4274-4284.
13. Leiding, T., Wang, J., Martinsson, J., DeGrado, W. F., and Arskold, S. P. (2010) Proton and cation transport activity of the M2 proton channel from influenza A virus. Proc Natl Acad Sci U S A 107, 15409-15414.
12. Cady, S. D., Schmidt-Rohr, K., Wang, J., Soto, C. S., DeGrado, W. F., and Hong, M. (2010) Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 463, 689-692.
11. Balannik, V., Obrdlik, P., Inayat, S., Steensen, C., Wang, J., Rausch, J. M., DeGrado, W. F., Kelety, B., and Pinto, L. H. (2010) Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity. Pflugers Archiv : European journal of physiology 459, 593-605.
10. Wang, J., Cady, S. D., Balannik, V., Pinto, L. H., DeGrado, W. F., and Hong, M. (2009) Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc 131, 8066-8076. Highlighted by ACS Chemical Biology.
9. Balannik, V.,# Wang, J.,# Ohigashi, Y., Jing, X., Magavern, E., Lamb, R. A., DeGrado, W. F., and Pinto, L. H. (2009) Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 48, 11872-11882.
At the National University of Singapore
8. Uttamchandani, M., Wang, J., Li, J., Hu, M., Sun, H., Chen, K. Y., Liu, K., and Yao, S. Q. (2007) Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library. J Am Chem Soc 129, 7848-7858.
7. Uttamchandani, M., Lee, W. L., Wang, J., and Yao, S. Q. (2007) Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays. J Am Chem Soc 129, 13110-13117.
6. Wang, J., Uttamehandani, M., Sun, H. Y., and Yao, S. Q. (2006) Small molecule microarrays: Applications using specially tagged chemical libraries. QSAR Comb Sci 25, 1009-1019.
5. Wang, J., Uttamchandani, M., Sun, L. P., and Yao, S. Q. (2006) Activity-based high-throughput profiling of metalloprotease inhibitors using small molecule microarrays. Chem Commun (Camb), 717-719.
4. Wang, J., Uttamchandani, M., Li, J., Hu, M., and Yao, S. Q. (2006) Rapid assembly of matrix metalloprotease inhibitors using click chemistry. Org Lett 8, 3821-3824.
3. Wang, J., Uttamchandani, M., Li, J., Hu, M., and Yao, S. Q. (2006) "Click" synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases. Chem Commun (Camb), 3783-3785. Highlighted as 'hot paper' by Chem. Commun., Chemical Society Magazine and Chemistry World.
2. Uttamchandani, M., Wang, J., and Yao, S. Q. (2006) Protein and small molecule microarrays: powerful tools for high-throughput proteomics. Mol Biosyst 2, 58-68.
1. Sun, H., Chattopadhaya, S., Wang, J., and Yao, S. Q. (2006) Recent developments in microarray-based enzyme assays: from functional annotation to substrate/inhibitor fingerprinting. Anal Bioanal Chem 386, 416-426.
Patents
DeGrado, W. F., Wang, J, Wang, J., Jo, H., Canturk, B. Inhibitors targeting drug-resistant influenza A. US14363116
DeGrado, W. F., Wang, J. Inhibitors of the influenza A virus M2 proton channel. US8569284
DeGrado, W. F., Wang, J. Inhibitors of the influenza A virus M2 proton channel. US9403777
DeGrado, W. F., Wang, J. Influenza A virus inhibition. US9464075
DeGrado, W. F., Wang, J. Adamantane analogs. US9301950
DeGrado, W. F., Wang, J. Spiro-piperidine inhibitors. US8557836
DeGrado, W. F., Wang, J. Inhibition of influenza A virus M2 proton channel. US9453005